
|Videos|June 14, 2014
An Analysis of IPMN and Pancreatic Cancer Outcomes
Tanios Bekaii-Saab, MD, Section Chief, Gastrointestinal Oncology, associate professor, Internal Medicine, Pharmacology, The Ohio State University, discusses an analysis of IPMN and pancreatic cancer.
Advertisement
Clinical Pearls
Tanios Bekaii-Saab, MD, Section Chief, Gastrointestinal Oncology, associate professor, Internal Medicine, Pharmacology, The Ohio State University, discusses an analysis of IPMN and pancreatic cancer.
- This analysis looked at the outcomes of patients with IPMN in the background of pancreatic cancer.
- It has been known that patients with IPMN do better than those with pancreatic cancer.
- Researchers hope that this data can help to identify and stratify patients to improve outcomes.
Advertisement
Advertisement
Advertisement
Trending on Targeted Oncology - Immunotherapy, Biomarkers, and Cancer Pathways
1
FDA Approves T-DXd Plus Pertuzumab for HER2-Positive Breast Cancer
2
Teclistamab/Daratumumab Earns FDA Priority Voucher for R/R Myeloma
3
Roxadustat Granted Orphan Drug Designation for Myelodysplastic Syndromes
4
FDA Fast-Tracks Muzastotug Combo in MSS Metastatic Colorectal Cancer
5










































